Agminated benign vascular tumour successfully treated with trametinib
Authors:
- 16 January 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (6) , 1195-1197
Abstract
Vascular tumours are caused by the neoplastic transformation of cells constituting vascular structures. Traditionally, treatment options include surgical approaches such as resection, embolization/sclerotherapy, or laser therapy, and medical treatments such as corticosteroids, beta‐blockers, and chemotherapy. The investigation of genetic mutations underlying vascular anomalies has recently provided new insights into the genetic aetiology of these lesions,1 giving rise to personalized, targeted medical treatment that may potentially be safer and more effective. Here, we describe a patient who presented with a reactive, locally disseminated vascular tumour that failed conventional treatments. Identifying a somatic mutation in the NRAS gene promoted the treatment with trametinib, which resulted in the rapid regression of the tumour.Keywords
This publication has 7 references indexed in Scilit:
- Theranostic Advances in Vascular MalformationsJournal of Investigative Dermatology, 2020
- BRAF and RAS Mutations in Sporadic and Secondary Pyogenic GranulomaJournal of Investigative Dermatology, 2016
- Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic GranulomaJournal of Investigative Dermatology, 2015
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- Agminated, Eruptive Pyogenic Granuloma‐Like Lesions Developing over Congenital Vascular StainsPediatric Dermatology, 2011
- Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis.Current Molecular Medicine, 2009
- PYOGENIC GRANULOMA RECUKRING WITH MULTIPLE SATELLITES.British Journal of Dermatology, 1968